Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Kent Rogerson

Psychiatry Stockton, CA Medical Doctor

NPI 1003926437 CMS profile 181893

2522 Grand Canal Blvd, #1, Stockton, CA 95207

Open in the dashboard

General payments

$5,008

331 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Kent Rogerson of Stockton, CA is reported in the CMS Open Payments database as having received $5,008 across 331 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,476 97
2021 General $960 60
2020 General $902 54
2019 General $1,669 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kent Rogerson
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kent Rogerson were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kent Rogerson Psychiatry median Middle half National median
2019 $1,669 $184 $59–$605 $163
2020 $902 $119 $36–$372 $114
2021 $960 $143 $43–$576 $132
2022 $1,476 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Takeda Pharmaceuticals U.S.A., Inc. $837 70 payments
  2. Lundbeck LLC $815 50 payments
  3. Sunovion Pharmaceuticals Inc. $790 49 payments
  4. Otsuka America Pharmaceutical, Inc. $489 31 payments
  5. Allergan Inc. $472 40 payments
  6. AbbVie, Inc. $348 28 payments
  7. Vanda Pharmaceuticals Inc. $214 8 payments
  8. Alkermes, Inc. $188 9 payments
  9. Shire North American Group Inc $165 12 payments
  10. Janssen Pharmaceuticals, Inc $162 9 payments
  11. Other $528 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,936 329 payments
  2. Education $72 2 payments
Products named General payments · program years 2019–2022
  1. LATUDA $790 49 payments
  2. TRINTELLIX $668 55 payments
  3. REXULTI Psychiatry $616 35 payments
  4. VRAYLAR Neuroscience $432 39 payments
  5. REXULTI Psychiatry $425 28 payments
  6. VRAYLAR Neuroscience $348 28 payments
  7. VYVANSE $217 16 payments
  8. HETLIOZ $214 8 payments
  9. FANAPT $214 8 payments
  10. BRINTELLIX $199 15 payments
  11. Other $2,031 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

331 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record